CAR-T Related Cytopenia Profile in Relapsed/Refractory Multiple Myeloma: Results of Patients Treated with ARI0002h, an Academic BCMA-Directed CAR-T Cell

被引：1

作者：

Oliver-Caldes, Aina ^{[1
]}

Gerardo Rodriguez-Lobato, Luis ^{[2
]}

Gonzalez-Calle, Veronica ^{[3
]}

Tovar, Natalia ^{[4
]}

Cabanas, Valentin ^{[5
]}

Rodriguez-Otero, Paula ^{[6
]}

Luis Reguera, Juan ^{[7
]}

Espanol-Rego, Marta ^{[8
]}

Martin-Antonio, Beatriz ^{[9
]}

Zabaleta, Aintzane ^{[10
]}

Lasa, Marta ^{[11
]}

Inoges, Susana ^{[11
]}

Lopez-Diaz de Cerio, Ascension ^{[11
]}

Paiva, Bruno ^{[12
]}

Varea, Sara ^{[13
]}

Saez-Penataro, Joaquin ^{[13
]}

Juan, Manel ^{[8
]}

Rosinol, Laura ^{[14
]}

Prosper, Felipe ^{[15
]}

Moraleda, Jose M. ^{[5
]}

Urbano-Ispizua, Alvaro ^{[16
]}

Pascal, Mariona ^{[8
]}

Mateos, Maria-Victoria ^{[17
]}

Fernandez de Larrea, Carlos ^{[2
]}

机构：

[1] Univ Barcelona, Dept Hematol, Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain

[2] Hosp Clin Barcelona, Dept Hematol, Amyloidosis & Myeloma Unit, Barcelona, Spain

[3] Hosp Univ Salamanca, Inst Invest Biomed Salamanca IBSAL, Salamanca, Spain

[4] Univ Barcelona, Hosp Clin, Inst Invest Biomed August Pi I Sunyer IDIBAPS, Amyloidosis & Myeloma Unit, Barcelona, Spain

[5] Univ Murcia, IMIB Arrixaca, Hosp Clin Univ Virgen Arrixaca, Murcia, Spain

[6] Clin Univ Navarra, CIBER ONC, IDISNA, CCUN,CIMA, Pamplona, Navarra, Spain

[7] Univ Seville, Hosp Univ Virgen Rocio CSIC CIBERONC, UGC Hematol, Inst Biomed Sevilla IBiS, Seville, Spain

[8] Univ Barcelona, Dept Immunol, Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain

[9] Fdn Jimenez Diaz, Inst Invest Sanitaria, Madrid, Spain

[10] Univ Navarra, Clin Univ Navarra, Ctr Invest Med Aplicada, IDISNA,CIBERONC, Pamplona, Spain

[11] Clin Univ Navarra, Ctr Invest Med Aplicada CIMA, CIBERONC Pamplona, IDISNA, Pamplona, Spain

[12] Clin Univ Navarra, Canc Ctr Univ Navarra CCUN, Ctr Invest Med Aplicada CIMA, Inst Invest Sanitaria Navarra IDISNA, Pamplona, Navarra, Spain

[13] Univ Barcelona, IDIBAPS, Hosp Clin Barcelona, Barcelona, Spain

[14] Hosp Clin Barcelona, IDIBAPS, Dept Hematol, Amyloidosis & Myeloma Unit, Barcelona, Spain

[15] Univ Navarra, Clin Univ Navarra, Ctr Invest Med Aplicada, Pamplona, Spain

[16] Hosp Clin Barcelona, Dept Hematol, Barcelona, Spain

[17] Univ Hosp Salamanca, IBSAL, Canc Res Ctr IBMCC USAL CSIC, Salamanca, Spain

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-166525

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：10347 / 10349

页数：3

共 50 条

[41] High Activation of BCMA CAR-T Cells Contributes to Increased Response Rate for Patients With Relapsed/Refractory Multiple Myeloma
Hu, Yongxian
Zhao, Houli
Chang, Alex Hongsheng
Nagler, Arnon
Huang, He
BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 51 - 51
[42] Mechanisms and salvage treatments in patients with multiple myeloma relapsed post-BCMA CAR-T cell therapy
Fu, Bingjie
Liu, Rui
Gao, Gongzhizi
Lin, Zujie
He, Aili
FRONTIERS IN IMMUNOLOGY, 2024, 15
[43] Safety and Efficacy of BCMA CAR-T Cell Therapy in Older Patients With Multiple Myeloma
Reyes, Kevin R.
Huang, Chiung-Yu
Lo, Mimi
Arora, Shagun
Chung, Alfred
Wong, Sandy W.
Wolf, Jeffrey
Olin, Rebecca L.
Martin, Thomas
Shah, Nina
Banerjee, Rahul
TRANSPLANTATION AND CELLULAR THERAPY, 2023, 29 (06): : 350 - 355
[44] Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma
Chenggong Li
Jia Xu
Wenjing Luo
Danying Liao
Wei Xie
Qiuzhe Wei
Yinqiang Zhang
Xindi Wang
Zhuolin Wu
Yun Kang
Jin’e Zheng
Wei Xiong
Jun Deng
Yu Hu
Heng Mei
Leukemia, 2024, 38 : 149 - 159
[45] BCMA CAR-T Therapy Is Safe and Effective for Refractory/Relapsed Multiple Myeloma With Central Nervous System Involvement
Wang, Yiyun
Zu, Cheng
Teng, Xinyi
Yang, Li
Zhang, Mingming
Hong, Ruimin
Zhao, Houli
Cui, Jiazhen
Xu, Huijun
Hongsheng, Alex Chang
Hu, Yongxian
Huang, He
JOURNAL OF IMMUNOTHERAPY, 2022, 45 (01) : 25 - 34
[46] Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma
Li, Chenggong
Xu, Jia
Luo, Wenjing
Liao, Danying
Xie, Wei
Wei, Qiuzhe
Zhang, Yinqiang
Wang, Xindi
Wu, Zhuolin
Kang, Yun
Zheng, Jin'e
Xiong, Wei
Deng, Jun
Hu, Yu
Mei, Heng
LEUKEMIA, 2024, 38 (01) : 149 - 159
[47] High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma
Yuanyan Tang
Haisen Yin
Xinying Zhao
Dan Jin
Yan Liang
Tao Xiong
Lu Li
Wen Tang
Jiangzhao Zhang
Min Liu
Zhuojun Yu
Huimin Liu
Sibin Zang
Zhiping Huang
Journal of Experimental & Clinical Cancer Research, 41
[48] Cardiovascular adverse events and outcomes after anti-BCMA CAR-T for relapsed and refractory multiple myeloma
Stefanie Palfi
Lauren C. Peres
Himara Koelmeyer
Melissa Alsina
Rachid C. Baz
Brandon J. Blue
Salvatore Corallo
Gabriel De Avila
Ciara Freeman
Rebecca Gonzalez
Ariel Grajales-Cruz
Kristy Harvey
Hien D. Liu
Taiga Nishihori
Guilherme H. Oliveira
Laura B. Oswald
Omar Castaneda Puglianini
Sruthi Selvakumar
Alexis Behne Sharma
Elicia Wang
Kenneth H. Shain
Michael Jain
Frederick L. Locke
Mohammed Alomar
Doris K. Hansen
Dae Hyun Lee
Blood Cancer Journal, 15 (1)
[49] High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma
Tang, Yuanyan
Yin, Haisen
Zhao, Xinying
Jin, Dan
Liang, Yan
Xiong, Tao
Li, Lu
Tang, Wen
Zhang, Jiangzhao
Liu, Min
Yu, Zhuojun
Liu, Huimin
Zang, Sibin
Huang, Zhiping
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2022, 41 (01)
[50] Sequential Administration of Selinexor and CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma
Gill, Sarvarinder Kaur
Biran, Noa
Phull, Pooja
Vesole, David H.
Siegel, David S.
Parmar, Harsh
BLOOD, 2023, 142

← 1 2 3 4 5 →